Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of CD33 antibody drug conjugates with chemotherapeutic agents

Combination of CD33 antibody drug conjugates with chemotherapeutic agents

US Patent 11110179 · Granted Sep 7, 2021

Estimated economic value: $257,634,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Shock absorbing swim goggles with independently movable lenses and method of use2025
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2023
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2022
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2020
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2019
Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates2018
Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates2017
Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates2015
Post-relapse treatment of CD30 expressing lymphomas2014